VIRO: Revenue up 173% in H1 2026, driven by a major U.S. partner order; net loss nearly halved
Waktu baca kurang dari 1 menit
Revenue surged 173% in H1 2026, mainly from a large U.S. partner order, while net loss nearly halved. Strategic focus shifted to scalable partnerships and regulatory progress was made with an FDA submission. Full-year guidance is maintained, but broad U.S. rollout is still pending.
Original document: ViroGates A/S [VIRO] Interim report — Aug. 21 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr